Silvergate announced that the Food and Drug Administration (FDA) has approved Epaned (enalapril maleate powder for oral solution) for two additional indications: treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease rate of development of overt heart failure and to reduce hospitalization for heart failure).
The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of the angiotensin-converting enzyme (ACE) results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion.
Epaned is already approved for the treatment of hypertension in patients aged ≥1 month. Epaned for Oral Solution is available in a 150mg/150mL strength in a kit containing the powder and diluent.
For more information call (855) 379-0382 or visit Epaned.com.